An update on the role of chronic rhinosinusitis with nasal polyps as a co-morbidity in severe asthma

References

• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373.
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European respiratory society/American thoracic society guideline. Eur Respir J. 2020;55(1):pii: 1900588.
   PubMed Web of Science ®Google Scholar
• Licari A, Brambilla I, Marseglia A, et al. Difficult vs. severe asthma: definition and limits of asthma control in the pediatric population. Front Pediatr. 2018;6:170.
   PubMed Web of Science ®Google Scholar
• Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410–419.
   PubMed Web of Science ®Google Scholar
• Licari A, Caimmi S, Bosa L, et al. Rhinosinusitis and asthma: a very long engagement. Int J Immunopathol Pharmacol. 2014;27(4):499–508.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Denicolò CF, et al. The nose and the lung: united airway disease? Front Pediatr. 2017;5:44.
   PubMed Web of Science ®Google Scholar
• Marseglia GL, Merli P, Caimmi D, et al. Nasal disease and asthma. Int J Immunopathol Pharmacol. 2011;24(4 Suppl):7–12.
   PubMed Web of Science ®Google Scholar
• Radhakrishna N, Tay TR, Hore-Lacy F, et al. Profile of difficult to treat asthma patients referred for systematic assessment. Respir Med. 2016;117:166–173.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Reddel H, McDonald VM, et al. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian xolair registry. Intern Med J. 2016;46(9):1054–1062.
   PubMed Web of Science ®Google Scholar
• Denlinger LC, Phillips BR, Ramratnam S, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med. 2017;195(3):302–313.
   PubMed Web of Science ®Google Scholar
• Licari A, Brambilla I, De Filippo M, et al. The role of upper airway pathology as a co-morbidity in severe asthma. Expert Rev Respir Med. 2017;11(11):855–865.
   PubMed Web of Science ®Google Scholar
• Tay TR, Radhakrishna N, Hore-Lacy F, et al. Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology. 2016;21(8):1384–1390.
   PubMed Web of Science ®Google Scholar
• McDonald VM, Hiles SA, Godbout K, et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology. 2019;24(1):37–47.
   PubMed Web of Science ®Google Scholar
• Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe—an underestimated disease. A GA(2)LEN study. Allergy. 2011;66:1216.
   PubMed Web of Science ®Google Scholar
• Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136:1431–1440.
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50:1–12.
   PubMed Web of Science ®Google Scholar
• Orlandi RR, Kingdom TT, Hwang PH, et al. International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(Suppl 1):S22–209.
   PubMed Web of Science ®Google Scholar
• Lund VJ, Mackay IS. Staging in rhinosinusitis. Rhinology. 1993;31:183–184.
   PubMedGoogle Scholar
• Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1–464.
   Google Scholar
• Chaaban MR, Walsh EM, Woodworth BA. Epidemiology and differential diagnosis of nasal polyps. Am J Rhinol Allergy. 2013;27(6):473–478.
   PubMed Web of Science ®Google Scholar
• Caimmi D, Matti E, Pelizzo G, et al. Nasal polyposis in children. J Biol Regul Homeost Agents. 2012;26(1 Suppl):S77–83.
   PubMedGoogle Scholar
• Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol. 2019;144:1–12.
   PubMed Web of Science ®Google Scholar
• Philpott CM, Erskine S, Hopkins C, et al. Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK national chronic rhinosinusitis epidemiology study. Respir Res. 2018;19(1):129.
   PubMed Web of Science ®Google Scholar
• Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45‐53.
   PubMed Web of Science ®Google Scholar
• Lin DC, Chandra RK, Tan BK, et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am J Rhinol Allergy. 2011;25:205–208.
   PubMed Web of Science ®Google Scholar
• Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U‐BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308‐1321.
   Web of Science ®Google Scholar
• Haselkorn T, Chen H, Miller DP, et al. Asthma control and activity limitations: insights from the real-world evaluation of asthma control and treatment (REACT) study. Ann Allergy Asthma Immunol. 2010;104(6):471–477.
   PubMed Web of Science ®Google Scholar
• Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian severe asthma registry (BSAR). Respir Med. 2014;108(12):1723–1732.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gevaert E, Lou H, et al. Chronic rhinosinusitis in Asia. J Allergy Clin Immunol. 2017;140(5):1230–1239.
   PubMed Web of Science ®Google Scholar
• Won HK, Kim YC, Kang MG, et al. Age-related prevalence of chronic rhinosinusitis and nasal polyps and their relationships with asthma onset. Ann Allergy Asthma Immunol. 2018;120(4):389–394.
   PubMed Web of Science ®Google Scholar
• Staikūniene J, Vaitkus S, Japertiene LM, et al. Association of chronic rhinosinusitis with nasal polyps and asthma: clinical and radiological features, allergy and inflammation markers. Medicina (Kaunas). 2008;44(4):257–265.
   PubMed Web of Science ®Google Scholar
• Alobid I, Benítez P, Bernal-Sprekelsen M, et al. Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments. Allergy. 2005;60(4):452–458.
   PubMed Web of Science ®Google Scholar
• Khan A, Huynh TMT, Vandeplas G, et al. The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life. Rhinology. 2019;57(5):343–351.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Malvezzi L, Blasi F, et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the severe asthma network Italy (SANI) registry. Respir Med. 2020;166:105947.
   PubMed Web of Science ®Google Scholar
• Heffler E, Bagnasco D, Canonica GW. Strategies to reduce corticosteroid-related adverse events in asthma. Curr Opin Allergy Clin Immunol. 2019;19(1):61–67.
   PubMed Web of Science ®Google Scholar
• Bassiouni A, Wormald PJ. Role of frontal sinus surgery in nasal polyp recurrence. Laryngoscope. 2013;123(1):36–41.
   PubMed Web of Science ®Google Scholar
• Loftus CA, Soler ZM, Koochakzadeh S, et al. Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors. Int Forum Allergy Rhinol. 2020;10(2):199–207.
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Mitsui C, Hayashi H, et al. Aspirin-exacerbated respiratory disease (AERD): current understanding of AERD. Allergol Int. 2019;68(3):289–295.
   PubMed Web of Science ®Google Scholar
• Håkansson K, Bachert C, Konge L, et al. Airway inflammation in chronic rhinosinusitis with nasal polyps and asthma: the United airways concept further supported. PLoS One. 2015;10(7):e0127228.
   PubMed Web of Science ®Google Scholar
• Hellings PW, Hens G. Rhinosinusitis and the lower airways. Immunol Allergy Clin North Am. 2009;29(4):733–740.
   PubMed Web of Science ®Google Scholar
• Allakhverdi Z, Comeau MR, Smith DE, et al. CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation. J Allergy Clin Immunol. 2009;123(2):472–478.
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Fokkens W. Nasal involvement in allergic asthma. Allergy. 2003;58(12):1235–1243.
   PubMed Web of Science ®Google Scholar
• Anfuso A, Ramadan H, Terrell A, et al. Sinus and adenoid inflammation in children with chronic rhinosinusitis and asthma. Ann Allergy Asthma Immunol. 2015;114(2):103–110.
   PubMed Web of Science ®Google Scholar
• Tan BK, Chandra RK, Pollak J, et al. Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;131(5):1350–1360.
   PubMed Web of Science ®Google Scholar
• Ryu G, Min C, Park B, et al. Bidirectional association between asthma and chronic rhinosinusitis: two longitudinal follow-up studies using a national sample cohort. Sci Rep. 2020;10(1):9589.
   PubMed Web of Science ®Google Scholar
• Hirsch AG, Yan XS, Sundaresan AS, et al. Five-year risk of incident disease following a diagnosis of chronic rhinosinusitis. Allergy. 2015;70(12):1613–1621.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Moore WC. Severe asthma phenotypes - how should they guide evaluation and treatment? J Allergy Clin Immunol Pract. 2017;5(4):901–908.
   PubMed Web of Science ®Google Scholar
• Bachert C, Gevaert P, Holtappels G, et al. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol. 2001;107:607–614.
   PubMed Web of Science ®Google Scholar
• Mygind N, Dahl R, Bachert C. Nasal polyposis, eosinophil dominated inflammation, and allergy. Thorax. 2000;55(suppl 2):S79–83.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Bachert C, Holtappels G, et al. Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy. 2003;58:371–379.
   PubMed Web of Science ®Google Scholar
• Patou J, Holtappels G, Affleck K, et al. Enhanced release of IgE-dependent early phase mediators from nasal polyp tissue. J Inflamm (Lond). 2009;6:11.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Marseglia A, et al. Dupilumab to treat type 2 inflammatory diseases in children and adolescents. Paediatr Drugs. 2020:22(3):295–310.
   PubMed Web of Science ®Google Scholar
• McGregor MC, Krings JG, Nair P, et al. Role of Biologics in Asthma. Am J Respir Crit Care Med. 2019;199(4):433–445.
   PubMed Web of Science ®Google Scholar
• Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50.
   PubMed Web of Science ®Google Scholar
• Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017;377(10):965–976.
   PubMed Web of Science ®Google Scholar
• Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol. 2017;12:331–357.
   PubMed Web of Science ®Google Scholar
• McLeod JJ, Baker B, Ryan JJ. Mast cell production and response to IL-4 and IL-13. Cytokine. 2015;75(1):57–61.
   PubMed Web of Science ®Google Scholar
• Kaur D, Hollins F, Woodman L, et al. Mast cells express IL-13R alpha 1: IL-13 promotes human lung mast cell proliferation and Fc epsilon RI expression. Allergy. 2006;61(9):1047–1053.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Cuppari C, Salpietro AM, et al. Serum IL-23 strongly and inversely correlates with FEV1 in asthmatic children. Int Arch Allergy Immunol. 2012;159(2):183–186.
   PubMed Web of Science ®Google Scholar
• Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015;15(5):271‐282.
   PubMed Web of Science ®Google Scholar
• Stevens WW, Lee RJ, Schleimer RP, et al. Chronic rhinosinusitis pathogenesis. J Allergy Clin Immunol. 2015;136(6):1442–1453.
   PubMed Web of Science ®Google Scholar
• Hamilos DL. Chronic rhinosinusitis endotyping: sharpening the focus on inflammation. J Allergy Clin Immunol. 2016;137(5):1457–1479.
   PubMed Web of Science ®Google Scholar
• Hammad H, Lambrecht BN. Barrier epithelial cells and the control of type 2 immunity. Immunity. 2015;43(1):29–40.
   PubMed Web of Science ®Google Scholar
• Sachse F, Becker K, von Eiff C, et al. Staphylococcus aureus invades the epithelium in nasal polyposis and induces IL-6 in nasal epithelial cells in vitro. Allergy. 2010;65(11):1430–1437.
   PubMed Web of Science ®Google Scholar
• Lan F, Zhang N, Gevaert E, et al. Viruses and bacteria in Th2-biased allergic airway disease. Allergy. 2016;71(10):1381–1392.
   PubMed Web of Science ®Google Scholar
• Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449–1456.e4.
   PubMed Web of Science ®Google Scholar
• Bachert C, Zhang N, Holtappels G, et al. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol. 2010;126(5):962–968.e9686.
   PubMed Web of Science ®Google Scholar
• Bachert C, Akdis CA. Phenotypes and emerging endotypes of chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4(4):621–628.
   PubMed Web of Science ®Google Scholar
• Stentzel S, Teufelberger A, Nordengrün M, et al. Staphylococcal serine protease-like proteins are pacemakers of allergic airway reactions to Staphylococcus aureus. J Allergy Clin Immunol. 2017;139(2):492–500.e8.
   PubMed Web of Science ®Google Scholar
• Ponikau JU, Sherris DA, Kephart GM, et al. Features of airway remodeling and eosinophilic inflammation in chronic rhinosinusitis: is the histopathology similar to asthma? J Allergy Clin Immunol. 2003;112(5):877–882.
   PubMed Web of Science ®Google Scholar
• Vreugde S, Wormald PJ. Innate lymphoid type 2 cells in chronic rhinosinusitis. Curr Opin Allergy Clin Immunol. 2016;16(1):7–12. 31.
   PubMed Web of Science ®Google Scholar
• Chen R, Smith SG, Salter B, et al. Allergen-induced increases in sputum levels of group 2 innate lymphoid cells in asthmatic subjects. Am J Respir Crit Care Med. 2017;196(6):700–712.
   PubMed Web of Science ®Google Scholar
• Roediger B, Weninger W. Group 2 innate lymphoid cells in the regulation of immune responses. Adv Immunol. 2015;125:111–154.
   PubMed Web of Science ®Google Scholar
• Poposki JA, Klingler AI, Tan BK, et al. Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps. Immun Inflamm Dis. 2017;5(3):233–243.
   PubMed Web of Science ®Google Scholar
• Lee TJ, Fu CH, Wang CH, et al. Impact of chronic rhinosinusitis on severe asthma patients. PLoS One. 2017;12(2):e0171047.
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312–2319.
   PubMed Web of Science ®Google Scholar
• Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–1204.
   PubMed Web of Science ®Google Scholar
• Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5–14.
   PubMed Web of Science ®Google Scholar
• Licari A, Manti S, Castagnoli R, et al. Targeted therapy for severe asthma in children and adolescents: current and future perspectives. Paediatr Drugs. 2019;21(4):215–237.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, De Filippo M, et al. Current and emerging biologic therapies for allergic rhinitis and chronic rhinosinusitis. Expert Opin Biol Ther. 2020;20(6):609–619.
   PubMed Web of Science ®Google Scholar
• Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315:469‐479.
   PubMed Web of Science ®Google Scholar
• Jonstam K, Swanson BN, Mannent LP, et al. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy. 2019;74:743–752.
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638–1650.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Marseglia GL, Castagnoli R, et al. From IgE to clinical trials of allergic rhinitis. Expert Rev Clin Immunol. 2015;11(12):1321–1333.
   PubMed Web of Science ®Google Scholar
• Licari A, Marseglia G, Castagnoli R, et al. The discovery and development of omalizumab for the treatment of asthma. Expert Opin Drug Discov. 2015;10(9):1033–1042.
   PubMed Web of Science ®Google Scholar
• Licari A, Marseglia A, Caimmi S, et al. Omalizumab in children. Paediatr Drugs. 2014;16(6):491–502.
   PubMed Web of Science ®Google Scholar
• Licari A, Manti S, Castagnoli R, et al. Immunomodulation in pediatric asthma. Front Pediatr. 2019;7:289.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Brambilla I, et al. New approaches for identifying and testing potential new anti-asthma agents. Expert Opin Drug Discov. 2018;13(1):51–63.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Panfili E, et al. An update on anti-ige therapy in pediatric respiratory diseases. Curr Resp Med Rev. 2017;13(1):22–29.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Denicolò C, et al. Omalizumab in children with severe allergic asthma: the Italian real-life experience. Curr Respir Med Rev. 2017;13(1):36–42.
   PubMed Web of Science ®Google Scholar
• Vennera Mdel C, Picado C, Mullol J, et al. Efficacy of omalizumab in the treatment of nasal polyps. Thorax. 2011;66(9):824–825.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–6.e1.
   PubMed Web of Science ®Google Scholar
• Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps. [ cited 2020 June 7]. Available from: https://www.novartis.us/news/media-releases/novartis-announces-fda-filing-acceptance-xolair-omalizumab-treatment-nasal
   Google Scholar
• Gevaert P, Bachert C, Corren J, et al. Omalizumab improves quality of life in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol. 2020;145(2):supplement, AB250.
   Web of Science ®Google Scholar
• Corren J, Bachert C, Gevaert P, et al. Omalizumab efficacy and safety in nasal polyposis: results from two parallel, double-blind, placebo-controlled trials. Ann Allergy Asthma Immunol. 2019;123(5):S17, D450.
   Web of Science ®Google Scholar
• Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–95.e1-8.
   Web of Science ®Google Scholar
• Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140(4):1024–1031.e14.
   PubMed Web of Science ®Google Scholar
• Chan R, RuiWen Kuo C, Lipworth B. Disconnect between effects of mepolizumab on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2020;8(5):1714–1716.
   PubMed Web of Science ®Google Scholar
• Effect of Mepolizumab in Severe Bilateral Nasal Polyps. [ cited 2020 June 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT03085797
   Google Scholar
• Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps. [ cited 2020 Aug 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT04157335
   Google Scholar
• Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis. [ cited 2020 Aug 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT03401229
   Google Scholar
• Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis. [ cited 2020 Aug 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT03450083
   Google Scholar
• Dennis SK, Lam K, Luong A. A review of classification schemes for chronic rhinosinusitis with nasal polyposis endotypes. Laryngoscope Investig Otolaryngol. 2016;1:130–134.
   PubMed Web of Science ®Google Scholar
• Liu XJ, Liao B, Yu QH, et al. IL-37-Mex3B-TLR3 axis in epithelial cells in eosinophilic chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020;145(1):160–172.
   PubMed Web of Science ®Google Scholar
• Ricciardolo F, Sorbello V, Folino A, et al. Identification of IL-17F/frequent exacerbator endotype in asthma. J Allergy Clin Immunol. 2017;140(2):395–406.
   PubMed Web of Science ®Google Scholar
• Sommer DD, Rotenberg BW, Sowerby LJ, et al. A novel treatment adjunct for aspirin-exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover trial. Int Forum Allergy Rhinol. 2016;6:385–391.
   PubMed Web of Science ®Google Scholar
• De Greve G, Hellings PW, Fokkens WJ, et al. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017;7:22.
   PubMed Web of Science ®Google Scholar